Latest Neuroendocrine tumor Stories
Pfizer Inc. announced on Thursday that it had halted a successful trial of its cancer drug Sutent after results showed the drug slowed the progression of a rare form of pancreatic cancer.
THE WOODLANDS, Texas, March 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr.
New president/CEO announces timely goals for established foundation WHITE PLAINS, N.Y., March 2 /PRNewswire/ -- Several high-profile cancers are infamous for being silent killers - but they are not the only cancers that catch victims by surprise. Carcinoid cancer can go undetected for many years.
NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F.
Patients with pancreatic cancer can now see all their physicians and receive the results of tests on the same day in the same place with the recent opening of the multidisciplinary clinic at the Elkins Pancreas Center in the Dan L. Duncan Cancer Center at Baylor College of Medicine in Houston.
- Data show significant 66% reduction in risk of disease progression versus placebo - Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on placebo - Results support Sandostatin LAR as first treatment after surgery in certain patients with newly diagnosed neuroendocrine tumors (NETs) EAST HANOVER, N.J., Jan.
Innovative Therapy Ensures Greater Patient Compliance, Improves Quality of Life MOUNTAIN VIEW, Calif., Jan. 13 /PRNewswire/ -- Based on its recent analysis of the biopharmaceuticals market, Frost & Sullivan recognizes Neotropix, Inc. with the 2009 U.S.
SAN DIEGO, Dec.
* Drug Candidate Will Advance to Phase 2 Clinical Trial in Carcinoid Patients * Potent Reduction in Serotonin Achieved * Drug Candidate Being Developed Under Fast Track Status From FDA THE WOODLANDS, Texas, Nov. 13, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.
Neotropix(R), Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today exciting data from an extensive pediatric preclinical study performed by the National Cancer Institute (NCI) funded Pediatric Preclinical Testing Program on the use of NTX-010 (Seneca Valley Virus-001), a tumor-selective naturally-occurring oncolytic virus.
- totally perplexed and mixed up.